Warp Speed’s Woodcock Encourages Institutions To Continue COVID-19 Plasma Controlled Trial
Executive Summary
Seeking to prevent negative fallout from emergency use authorization, Woodcock and NIH Director Collins ask investigators to prioritize a controlled trial of convalescent plasma currently underway in outpatients.
You may also be interested in...
Initial COVID-19 Vaccine Rollout Seems Bound To Disappoint
National Academy of Medicines draft on equitable COVID-19 vaccine allocation needs more overt strategies to address equity, commenters say. Meanwhile, competing national and state efforts to address COVID-19 vaccination allocation could lead to confusion as the country struggles to fairly divide limited resources among many high-risk populations.
FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization
Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.
Convalescent Plasma EUA Will Not Complicate Hyperimmune Globulin Product Development, Sponsors Say
US FDA authorization will further boost already-high demand for plasma from individuals recovered from COVID-19 and increase competition for donors, NYU’s Arthur Caplan predicts, but CoVIg-19 Plasma Alliance and Emergent BioSolutions say they do not expect EUA to impact either product supply or enrollment in upcoming randomized trials of their H-Ig products.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: